The customer contacted applied biocode with a request to review results for evidence of possible carryover.Three runs conducted between (b)(6) 2020 had a higher than anticipated amount of positive results for sars-cov-2 assay testing.The runs were performed using the same lots of reagents.Run data was reviewed, no patterns were detected that pointed to possible carryover on the biocode mdx system.The king fisher extraction method that is being used at this facility is not one that is referenced in our instructions for use.The customer has also reported that new technicians are performing the testing and that some sets of samples may be pooled for testing, pre-analytical error is a possible source of the elevated positivity rate for these runs.Although there is no report of an adverse event or direct evidence of an applied biocode device malfunction we are making this report out of an abundance of caution.Correction of manufacturer report number provided 04/20/2021.
|
End user had 3 runs that have high covid positivity, they repeated the three runs and the positivity rate was much lower.The original and repeat were separate extractions on the king fisher extraction system.The repeat was fresh extraction from the original sample.Run (b)(4) had 59 positive patient samples (s/n (b)(4)), the repeat (b)(4) had 6 positive patient samples (s/n (b)(4)).Run (b)(4) had 54 positive patient samples (s/n (b)(4)), the repeat (b)(4) had 14 positive patient samples ((b)(4)).Run (b)(4) had 23 positive patient samples (s/n (b)(4)), the repeat was repeated by another method and customer did not provide repeat information.The first results were not reported to the ordering physician, only the repeat run was reported to the ordering physician.There does not appear to be a pattern on the plate that would indicate in instrument issue, and plates were run on different instruments.
|